Safety of Peri-Operative Low-Dose Aspirin as a Part of Multimodal Venous Thromboembolic Prophylaxis for Total Knee and Hip Arthoplasty

Abstract

Purpose.

To examine whether it is safe to continue low-dose (100 mg/day) aspirin perioperatively as a part of standard multimodal venous thromboembolic prophylaxis for total hip arthroplasty (THA) or total knee arthroplasty (TKA).

Methods.

79 women and 60 men aged 52 to 91 years who underwent THA (n=50) or TKA (n=89) were prospectively studied. Preoperatively, 63 of the patients were on 100 mg of aspirin every morning for various medical reasons and continued in the perioperative period, except for the operation day. The remaining 76 patients were controls. Pre- and post-operative haemoglobin levels, postoperative blood drainage, and the amount of reinfused drained blood were recorded. Intra-operative blood loss and operative times were recorded for THA only. These parameters for the aspirin and control groups were compared.

Results.

All the parameters, namely blood loss (intraoperative and postoperative), operative time, surgical wound healing, and drop in the haemoglobin level (determined on day 3) did not differ significantly between the 2 groups.

Conclusion.

It is safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis.

Keywords

arthroplasty,replacement,hip arthroplasty,replacement,knee aspirin complications perioperative period safety thromboembolism

References

Robinson

Christie

Malcolm-Smith

. Nonsteroidal anti-inflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993;8:607–10.

Fauno

Petersen

Husted

. Increased blood loss after preoperative NSAID. Retrospective study of 186 hip arthroplasties. Acta Orthop Scand 1993;64:522–4.

Weale

Warwick

Durant

Prothero

. Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement? Ann R Coll Surg Engl 1995;77:35–7.

Vane

. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–5.

Amrein

Ellman

Harris

. Aspirin-induced prolongation of bleeding time and perioperative blood loss. JAMA 1981;245:1825–8.

Lotke

. Aspirin prophylaxis for thromboembolic disease after total joint arthroplasty. Am J Orthop (Belle Mead NJ) 2007;36(9 Suppl):14–5.

Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295–302.

Collaborative overview of randomised trials of antiplatelet therapy—Ill: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:235–46.

Maulaz

Bezerra

Michel

Bogousslavsky

. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005;62:1217–20.

10.

Burger

Chemnitius

Kneissl

Rucker

. Low-dose aspirin for secondary cardiovascular prevention: Cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: Review and meta-analysis. J Intern Med 2005;257:399–414.